Antonio Gonzalez Mart | Authors


Niraparib Maintenance Improves PFS in Frontline Ovarian Cancer

January 20, 2020

Antonio Gonzalez Martín, MD, discusses the results from the phase III PRIMA study, which evaluated the PARP inhibitor niraparib versus placebo as a frontline treatment of patients with newly diagnosed ovarian cancer who responded to platinum-based chemotherapy.